• BioOptix signs development agreement with Alcon
• Tutelix Cohort 2 patient recruitment and treatment progressing
• Tegenix and TegenEOS on track for FDA 510(k) clearance

Tetratherix Limited (ASX: TTX) has released its Q2 FY26 quarterly activities report, showcasing continued progress across its diverse product portfolio. Key highlights include the signing of a development agreement between Tetratherix's strategic partner BioOptix and Alcon, focused on ophthalmic biomaterial technologies. In the urology segment, the company's joint venture Tutelix is advancing patient recruitment and treatment in Cohort 2 of its clinical trial. Tetratherix's bone regeneration products, Tegenix and TegenEOS, are on track for FDA 510(k) clearance. The company has also confirmed its eligibility for the Australian government's R&D tax incentive program, allowing it to claim overseas expenditure in addition to Australian activities. Tetratherix has strengthened its board with the appointment of Peter Gray as an independent non-executive director and Jacob Pfeffer as Company Secretary. Construction has commenced on the company's new advanced manufacturing facility in Alexandria, New South Wales, to support near-term dental applications and the longer-term pipeline. Tetratherix maintains a strong cash position of $21.6 million as of 31 December 2025, with zero debt financing, allowing it to continue investing in R&D and expansion.

Tetratherix expects to achieve FDA 510(k) clearance for its Tegenix and TegenEOS bone regeneration products in FY27.

Tetratherix is focused on progressing the regulatory clearance path for its Tegenix and TegenEOS products, initiating the third cohort of the TetraDerm clinical trial, securing capital funding for the Tutelix joint venture, and completing the pre-clinical studies for the BioOptix strategic partnership in FY26.